BioMarin Pharmaceuticals Inc (BMRN) Financials
Key financial figures for BioMarin Pharmaceuticals Inc (Q2 2026).
BioMarin Pharmaceutical Inc. reported revenue of $989.7 million for Q2 FY2026, up 19.9% from the same period a year earlier. Net income was $44.8 million, or $0.23 per share. Operating margin came to 11.21%, against 33.55% a year earlier. Free cash flow for the period was $139.3 million. Across the last 5 reported quarters, quarterly revenue has risen from $825.4 million in Q2 FY2025 to $989.7 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for BioMarin Pharmaceutical Inc. are on the SentiSense financials page.
- Revenue
- $990M
- Net Income
- $45M
- EPS
- $0.23
- Total Assets
- $11.7B
- Operating Cash Flow
- $168M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $990M | $45M | $0.23 | 11.21% | $139M |
| Q1 FY2026 | $766M | $106M | $0.54 | 16.92% | $200M |
| Q4 FY2025 | $875M | -$47M | -$0.22 | 9.08% | $59M |
| Q3 FY2025 | $776M | -$31M | -$0.16 | -6.02% | $335M |
| Q2 FY2025 | $825M | $241M | $1.23 | 33.55% | $168M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.2B | $349M | $1.80 | 16.56% | $725M |
| FY2024 | $2.9B | $427M | $2.21 | 16.97% | $475M |
| FY2023 | $2.4B | $168M | $0.88 | 7.68% | $52M |
Frequently asked questions
What was BioMarin Pharmaceutical Inc.'s revenue last quarter?
BioMarin Pharmaceutical Inc. reported revenue of $989.7 million for Q2 FY2026, up 19.9% from the same period a year earlier.
Is BioMarin Pharmaceutical Inc. profitable?
Yes. BioMarin Pharmaceutical Inc. reported net income of $44.8 million for Q2 FY2026, a net margin of 4.52% on revenue.
How has BioMarin Pharmaceutical Inc.'s margin trended?
Operating margin was 11.21% in Q2 FY2026, compared with 33.55% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did BioMarin Pharmaceutical Inc. generate?
BioMarin Pharmaceutical Inc. generated free cash flow of $139.3 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for BioMarin Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.